Search

Your search keyword '"Craxì, A"' showing total 3,147 results

Search Constraints

Start Over You searched for: Author "Craxì, A" Remove constraint Author: "Craxì, A"
3,147 results on '"Craxì, A"'

Search Results

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

3. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

4. Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity

5. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

6. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

7. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

8. A global research priority agenda to advance public health responses to fatty liver disease

9. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

10. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

11. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

13. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

16. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

17. Health Care at the Time of COVID-19

20. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

21. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

22. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

23. Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study

24. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.

25. The Equitable Benefit Approach to guide the assessment of medical and psychosocial factors in liver transplant candidacy.

26. Meet–Test–Treat for HCV management: patients’ and clinicians’ preferences in hospital and drug addiction services in Italy

27. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions

28. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

30. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

31. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

33. Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey

34. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

35. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

39. Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development

40. A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease

41. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

42. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

47. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

48. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

49. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

50. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Catalog

Books, media, physical & digital resources